| Browse All

BioAge Labs, Inc. (BIOA)

Healthcare | Drug Manufacturers - Specialty & Generic | Emeryville, United States | NasdaqGS
18.49 USD +1.50 (8.829%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 18.49

Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 1:21 p.m. EDT

BioAge Labs (BIOA) presents a mixed picture. While the stock has shown some short-term momentum with recent price fluctuations, the overall fundamentals are weak, with negative earnings and a high overall risk rating. The lack of dividends and poor financial performance make it unsuitable for dividend-focused investors. Short-term traders may find opportunities in the range-bound price action, but the low volatility and mixed options activity suggest caution. Long-term investors should be wary due to the company's financial instability and uncertain future growth prospects.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.519980
AutoARIMA0.525704
AutoTheta0.531258
AutoETS0.549703

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 41%
H-stat 34.92
Ljung-Box p 0.000
Jarque-Bera p 0.139
Excess Kurtosis -1.34
Attribute Value
Sector Healthcare
Debt to Equity Ratio 2.044
Revenue per Share 0.25
Market Cap 820,581,632
Forward P/E -6.66
Website https://bioagelabs.com

As of April 11, 2026, 1:21 p.m. EDT: Options activity indicates mixed sentiment. There is a notable presence of puts with high open interest at strikes around $15 and $17.5, suggesting some bearish positioning. However, there are also calls with significant open interest at higher strikes, indicating potential bullish speculation. The overall volatility is low, with IV at or near zero for many expirations, which may indicate a lack of directional conviction. The recent price action shows a range-bound trend with limited upward momentum, suggesting traders are cautious. The presence of new flows at higher strikes could signal a potential breakout or continued consolidation.


Info Dump

Attribute Value
52 Week Change 3.5995026
Address1 5,885 Hollis Street
Address2 Suite 370
All Time High 26.62
All Time Low 2.88
Ask 18.94
Ask Size 3
Audit Risk 8
Average Daily Volume10 Day 353,630
Average Daily Volume3 Month 607,545
Average Volume 607,545
Average Volume10Days 353,630
Bid 18.06
Bid Size 3
Board Risk 2
Book Value 7.277
City Emeryville
Compensation As Of Epoch Date 1,735,603,200
Compensation Risk 9
Country United States
Crypto Tradeable 0
Currency USD
Current Price 18.49
Current Ratio 14.241
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 18.9
Day Low 17.2
Debt To Equity 2.044
Display Name BioAge Labs
Earnings Timestamp 1,774,355,400
Earnings Timestamp End 1,777,984,200
Earnings Timestamp Start 1,777,984,200
Ebitda -92,567,000
Ebitda Margins 0.0
Enterprise To Ebitda -5.888
Enterprise To Revenue 60.594
Enterprise Value 545,043,648
Eps Current Year -2.59986
Eps Forward -2.77608
Eps Trailing Twelve Months -2.24
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 19.2129
Fifty Day Average Change -0.7229004
Fifty Day Average Change Percent -0.037625782
Fifty Two Week Change Percent 359.95026
Fifty Two Week High 24.0
Fifty Two Week High Change -5.51
Fifty Two Week High Change Percent -0.22958334
Fifty Two Week Low 3.67
Fifty Two Week Low Change 14.82
Fifty Two Week Low Change Percent 4.038147
Fifty Two Week Range 3.67 - 24.0
Financial Currency USD
First Trade Date Milliseconds 1,727,357,400,000
Float Shares 37,011,383
Forward Eps -2.77608
Forward P E -6.660471
Free Cashflow -54,844,124
Full Exchange Name NasdaqGS
Full Time Employees 60
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,775,001,600
Gross Margins 0.0
Gross Profits -64,971,000
Has Pre Post Market Data 1
Held Percent Insiders 0.02434
Held Percent Institutions 0.6128
Implied Shares Outstanding 44,379,753
Industry Drug Manufacturers - Specialty & Generic
Industry Disp Drug Manufacturers - Specialty & Generic
Industry Key drug-manufacturers-specialty-generic
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Long Name BioAge Labs, Inc.
Market us_market
Market Cap 820,581,632
Market State CLOSED
Max Age 86,400
Message Board Id finmb_529779470
Most Recent Quarter 1,767,139,200
Net Income To Common -80,605,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 820,581,632
Number Of Analyst Opinions 6
Open 17.38
Operating Cashflow -81,627,000
Operating Margins -9.234241
Overall Risk 7
Payout Ratio 0.0
Phone 510 806 1445
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 18.49
Post Market Time 1,776,464,176
Previous Close 16.99
Price Eps Current Year -7.1119213
Price Hint 2
Price To Book 2.540882
Price To Sales Trailing12 Months 91.22642
Profit Margins 0.0
Quick Ratio 14.056
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 1.5
Regular Market Change Percent 8.82872
Regular Market Day High 18.9
Regular Market Day Low 17.2
Regular Market Day Range 17.2 - 18.9
Regular Market Open 17.38
Regular Market Previous Close 16.99
Regular Market Price 18.49
Regular Market Time 1,776,456,001
Regular Market Volume 483,648
Return On Assets -0.17757
Return On Equity -0.27086002
Revenue Per Share 0.25
Sand P52 Week Change 0.38150132
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 8
Shares Outstanding 44,379,753
Shares Percent Shares Out 0.035099998
Shares Short 1,559,461
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 1,276,379
Short Name BioAge Labs, Inc.
Short Percent Of Float 0.0399
Short Ratio 2.51
Source Interval 15
State CA
Symbol BIOA
Target High Price 73.0
Target Low Price 23.0
Target Mean Price 53.33333
Target Median Price 56.0
Total Cash 281,097,984
Total Cash Per Share 6.334
Total Debt 5,560,000
Total Revenue 8,995,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -2.24
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 11.225775
Two Hundred Day Average Change 7.264225
Two Hundred Day Average Change Percent 0.64710236
Type Disp Equity
Volume 483,648
Website https://bioagelabs.com
Zip 94,608